Headed by Professor John McNeil, ASPREE (ASPrin in Reducing Events in the Elderly) investigators secured a further $1.5 million from the Victorian Cancer Agency, through the Department of Health for the ASPREE Trial. The ASPREE trial is investigating whether low dose Aspirin can delay or prevent the onset of common age related disease such as cardiovascular disease, dementia and certain cancers in healthy people aged 70 and over.
Monday 17 June 2013
ASPREE Secures more Funding
Headed by Professor John McNeil, ASPREE (ASPrin in Reducing Events in the Elderly) investigators secured a further $1.5 million from the Victorian Cancer Agency, through the Department of Health for the ASPREE Trial. The ASPREE trial is investigating whether low dose Aspirin can delay or prevent the onset of common age related disease such as cardiovascular disease, dementia and certain cancers in healthy people aged 70 and over.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment